New drug for advanced lung cancer after standard treatment fails
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new drug called JSKN016 in people with advanced non-small cell lung cancer whose standard treatments have stopped working. The drug may help shrink tumors or slow the cancer's growth, and the study looks at safety and effectiveness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with advanced lung cancer (non-small cell) that cannot be removed with surgery or cured with radiation
- Your cancer has a specific gene change (like EGFR) and you've already tried an EGFR pill, OR your cancer has no known driver mutation and you've had immunotherapy and chemotherapy, OR you have another driver mutation and the standard treatment didn't work
- You are able to take care of yourself and are not bedridden (performance status 0 or 1)
- You do not have active brain metastases or cancer in the brain lining
- You haven't been treated with certain prior drugs like docetaxel or ADC drugs (such as DS-8201 or Trodelvy)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination for people with advanced non-small cell lung cancer (NSCLC) that cannot be removed with surgery or cured with radiation. It aims to see if the combination is safe and effective.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This trial tests a new drug called SSGJ-707 for people with advanced non-small cell lung cancer who have not had prior treatment. It aims to see if the drug can help shrink tumors and improve outcomes.
This trial tests a new drug called JSKN016 for people with advanced cancer that has not responded to other treatments. It focuses on certain lung and breast cancers with specific genetic markers.
This trial tests a new drug called SSGJ-706, either alone or with other treatments, for people with advanced non-small cell lung cancer (NSCLC) that has spread or cannot be surgically removed. The goal is to see if it helps shrink or control the cancer.
This trial tests a new drug combination for a type of lung cancer called squamous non-small cell lung cancer. It aims to see if the combination can help people whose cancer has grown after standard treatments.
Hear when a new Advanced Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.